menu
    • menu

    Company profile for Design Therapeutics

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. Our GeneTAC™ molecules are designed to selectively bind to genetic repeat sequences, modulate gene expression either by...
    Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions. The company’s lead program is focused on the treatment of Friedreich’s ataxia and discovery efforts are ongoing in other degenerative diseases. Our GeneTAC™ molecules are designed to selectively bind to genetic repeat sequences, modulate gene expression either by restoring or blocking transcription, and restore cellular health. As a platform, we believe that GeneTAC™ molecules have broad potential applicability across monogenic nucleotide repeat expansion diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Design TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    6005 Hidden Valley Road Suite 110 Carlsbad, CA 9201
    Telephone
    Telephone
    858-293-4900
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.designtx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/designtx/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Design Therapeutics Reveals Q1 2026 Financials & Business
    Design Therapeutics Reveals Q1 2026 Financials & Business

    28 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7233843

    FIRSTWORD PHARMA
    28 Apr 2026
    Share Share
    Design Therapeutics Reports Q4 2025 Financial Results
    Design Therapeutics Reports Q4 2025 Financial Results

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3252281/0/en/Design-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Recent-Business-Updates.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Design Therapeutics To Join Investor Conferences
    Design Therapeutics To Join Investor Conferences

    18 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/18/3240139/0/en/Design-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    18 Feb 2026
    Share Share
    Design Therapeutics To Join Investor Conferences
    Design Therapeutics To Join Investor Conferences

    26 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/26/3195087/0/en/Design-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    26 Nov 2025
    Share Share
    Design Therapeutics To Start DT-818 Dosing In DM1 Patients By H1
    Design Therapeutics To Start DT-818 Dosing In DM1 Patients By H1

    05 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/05/3181900/0/en/Design-Therapeutics-Announces-Plans-to-Initiate-Patient-Dosing-of-DT-818-in-Myotonic-Dystrophy-Type-1-DM1-in-the-First-Half-of-2026-and-Reports-Third-Quarter-2025-Financial-Results.html

    GLOBENEWSWIRE
    05 Nov 2025
    Share Share
    Design Therapeutics Appoints Justin Gover to Board of Directors
    Design Therapeutics Appoints Justin Gover to Board of Directors

    10 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/10/3148218/0/en/Design-Therapeutics-Appoints-Justin-Gover-to-Board-of-Directors.html

    GLOBENEWSWIRE
    10 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search